Bristol-Myers Squibb Company(BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Latest News & Analysis
Bristol-Myers Squibb Company: Strategic Immunology Venture and Financial Analysis
Bristol-Myers Squibb partners with Bain Capital to form a new immunology venture, reshaping its R&D focus amid significant financial shifts and market dynamics.
Bristol-Myers Squibb's Strategic Immunology Venture and Financial Update - Monexa AI
Explore Bristol-Myers Squibb's $300M immunology partnership with Bain Capital, its impact on pipeline, Q2 earnings outlook, and financial health analysis.
Bristol-Myers Squibb Company (BMY) Strategic Pivot with Eliquis Direct-to-Patient Program and Financial Insights
Bristol-Myers Squibb's new Eliquis direct-to-patient program offers 40%+ discounts, reshaping market access amid strong financial shifts and competitive pressures.
Bristol-Myers Squibb Company (BMY) Growth Strategy and Financial Update Amid BioNTech Partnership
Explore Bristol-Myers Squibb's strategic pivot with the $3.5B BioNTech deal, Q2 earnings beat, and pipeline advances shaping its growth and valuation.
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Preview and Strategic Growth Insights
Detailed analysis of Bristol-Myers Squibb's Q2 2025 earnings outlook, pipeline catalysts, patent cliff challenges, and financial metrics shaping investor decisions.
Bristol-Myers Squibb Company (BMY) Latest Financial Analysis & Strategic Growth Update
Explore Bristol-Myers Squibb's recent financial results, pipeline advances, and strategic pivots shaping its growth amid patent challenges and competitive pharma markets.
Bristol-Myers Squibb Growth Transition: Navigating Patent Cliffs and Sustaining Dividends | Monexa AI Analysis
Explore Bristol-Myers Squibb's strategic shift balancing legacy declines with new drug growth, financial health, and dividend sustainability amid evolving market dynamics.
Bristol-Myers Squibb (BMY) Latest Financial Analysis and Growth Strategy Insights
Explore Bristol-Myers Squibb's recent financial performance, strategic growth drivers, and implications for investors amid legacy drug declines and pipeline expansions.
Bristol-Myers Squibb Company (BMY) Strategic Growth and Financial Analysis Q2 2025
Bristol-Myers Squibb's strategic initiatives and new drug launches drive revenue growth, offsetting legacy patent cliffs while maintaining strong financial health.
Bristol-Myers Squibb Company (BMY) Strategic Pivot and Financial Health Analysis
Explore Bristol-Myers Squibb's recent stock trends, strategic partnerships, oncology pipeline growth, and dividend sustainability amid patent expirations.
Bristol Myers Faces Antitrust Challenge Over Pomalyst
Cigna's antitrust lawsuit against Bristol Myers Squibb over Pomalyst alleges patent fraud, sham litigation, and pay-for-delay tactics, impacting BMY's market position.
Bristol-Myers Squibb: Navigating Patent Cliffs with Strategic Innovation
Bristol-Myers Squibb navigates a complex period with clinical triumphs like Breyanzi's TRANSCEND FL data amidst the looming Eliquis patent cliff and strategic shifts.
Bristol-Myers Squibb (BMY): Pipeline Advances & Financial Dynamics
Bristol-Myers Squibb (BMY) showcases strong pipeline advancements, particularly with Sotyktu and OncoACP3, amidst Q2 2025 earnings forecasts.
Bristol-Myers Squibb (BMY): Financials, Pipeline, and Strategic Shifts Analyzed
Deep dive into Bristol-Myers Squibb's recent Sotyktu trial success, OncoACP3 licensing deal, financials, and strategic partnerships shaping its market position.
Bristol-Myers Squibb: Strategic Shifts and Financial Landscape in 2025
Bristol-Myers Squibb navigates strategic shifts with key partnerships and regulatory wins, balancing robust pipeline investment against recent financial fluctuations.
Bristol-Myers Squibb (BMY): Dividend Safety, Patents, and FDA
Bristol-Myers Squibb (BMY) navigates patent expirations, tariff threats, and market volatility. A data-driven analysis of BMY's financials and FDA approvals.
Bristol Myers Squibb (BMY): Opdivo, Dividends, and Market Challenges
Bristol Myers Squibb (BMY) navigates market volatility with Opdivo's growth, cost cuts, and dividend focus amidst revenue decline forecasts. Key insights for investors.
Bristol-Myers Squibb (BMY): Opdivo's European Approval, Debt Concerns, and Investor Outlook
Bristol-Myers Squibb (BMY) navigates Opdivo's European expansion amid debt concerns. A defensive stock with value potential, yet faces market volatility. Investors should weigh these factors.
Bristol-Myers Squibb (BMY): Navigating Challenges and Driving Growth
Bristol-Myers Squibb (BMY) faces Revlimid LOE but focuses on growth portfolio expansion and cost-cutting. Breyanzi's EU approval is a key growth driver.
Bristol-Myers Squibb (BMY): Breyanzi Approval, 2seventy Bio Deal & Dividend Strategy
Bristol-Myers Squibb (BMY) navigates acquisitions, regulatory approvals, and market dynamics. A look at Breyanzi's approval, the 2seventy bio deal, and dividend strategy.
Bristol-Myers Squibb (BMY): Acquisition Strategy, Dividend Dilemma, and Growth Prospects
BMY faces a complex landscape with its acquisition of 2seventy bio under scrutiny, Sotyktu showing promise, and questions arising over dividend sustainability.
Bristol Myers Squibb (BMY): Oncology Strategy and Financial Outlook
Bristol Myers Squibb (BMY) navigates strategic acquisitions, clinical trial successes, and cost-cutting to maintain market position and dividend sustainability.
Bristol-Myers Squibb (BMY): Navigating Revenue Transition and Growth
Bristol-Myers Squibb (BMY) navigates revenue transition with new drugs, cost cuts. Sotyktu's success & Opdivo's EU approval offer growth. A defensive, high-yield dividend stock.
Bristol-Myers Squibb (BMY): Opdivo Approval, Acquisitions, and Market Outlook
Bristol-Myers Squibb (BMY) navigates patent expirations with strategic acquisitions and cost-cutting. Opdivo's EU approval and pipeline expansion offer growth potential.
Bristol-Myers Squibb (BMY): Navigating Patent Expirations and Pipeline Development
Bristol-Myers Squibb (BMY) navigates patent expirations, pipeline development, and a shifting market. FDA reviews, oncology advancements, and dividend strategies shape its future.
Bristol Myers Squibb (BMY): FDA Approvals, Oncology Growth, and Dividend Analysis
Bristol Myers Squibb (BMY) navigates patent expirations, oncology growth, and strategic collaborations. FDA actions and dividend appeal shape investor attention.
Bristol-Myers Squibb (BMY): Oncology Pipeline, Dividend Strategy, and Future Outlook
Bristol-Myers Squibb (BMY) navigates oncology advancements, pipeline challenges, and financial pressures. Strategic partnerships and innovation balance stability. Market rotation favors dividend stocks.
Bristol Myers Squibb: Navigating Patent Cliffs, Driving Growth
Bristol Myers Squibb navigates patent expirations with new drugs, strategic partnerships, and cost cuts. FDA reviews Opdivo/Yervoy, Breyanzi sales surge, and BioArctic collaborates.
Bristol Myers Squibb: Pipeline Developments, Market Impact, and Industry Trends
Bristol Myers Squibb (BMY) is expanding its pipeline with strategic collaborations and robust drug data amidst competitive industry challenges.
Bristol Myers Squibb: Pipeline Progress & Patent Cliff Challenges
Bristol Myers Squibb navigates pipeline advancements amid patent cliff challenges, with Opdivo, Sotyktu, and Breyanzi updates influencing investor sentiment.
Bristol Myers Squibb: Market Developments and Strategic Outlook
Explore the latest developments, trials, and licensing agreements at BMY, impacting its competitive landscape and market outlook.
Bristol Myers Squibb: Pipeline Progress Amidst Patent Expiration Challenges
Intraday update on BMY’s breakthroughs in immuno‐oncology, robust pipeline data, and strategic financial moves.
Bristol-Myers Squibb Strategic Reorganization and Pipeline Developments
Detailed analysis of BMY's reorganization, pipeline developments, and financial challenges amid patent expirations and a strong dividend strategy.